Marilyne Labrie

Financement

• Subvention. Colloque 'Signalisation Quebec 2024'. Canadian Institutes of Health Research (Ottawa, Canada). 10 000 $. (2023-2024).
  Numéro de subvention : 202302PCS. Voir plus
• Subvention. Development of Personalized Therapies for Ovarian Cancer Patients. Canada Foundation for Innovation (Ottawa, Canada). 173 569 $. (2022).
  Numéro de subvention : 42746. Voir plus
• Subvention. Building of a functional single cell proteomics resource for the study the DNA damage response. Natural Sciences and Engineering Research Council (Ottawa, Canada). 12 500 $. (2022-2023).
  Numéro de subvention : DGECR-2022-00269. Voir plus
• Subvention. Building of a functional single cell proteomics resource for the study the DNA damage response. Natural Sciences and Engineering Research Council (Ottawa, Canada). 26 000 $. (2022-2023).
  Numéro de subvention : RGPIN-2022-03973. Voir plus
• Subvention. Development of Personalized Therapies for Ovarian Cancer Patients. Canadian Institutes of Health Research (Ottawa, Canada). 600 000 $. (2022-2027).
  Numéro de subvention : 202110CRC. Voir plus
• Subvention. Overcoming resistance to chemotherapy and immune checkpoint inhibitors in ovarian cancer. Ovarian Cancer Canada (Toronto, Canada). (2021-2023).
  Numéro de subvention : 31495_1. Voir plus
• Subvention. Synergistic lethality of PARP and PI3K pathway inhibitors in ovarian cancer. Ovarian Cancer Research Alliance (New York, États-Unis). 75 000 USD. (2019-2021).
  Numéro de subvention : 599404. Voir plus
• Bourse. Expression of Galectins in high grade serous ovarian cancer. Canadian Institutes of Health Research (Ottawa, Canada). Travel award. 1 000 $. (2016-2017).
  Numéro de subvention : grant.18b95a11b0af41ba7230daff94e6947d. Voir plus
• Bourse. Galectins as biomarkers in ovarian cancer. Biomed Conference (Montreal, Canada). 125 $. (2016).
• Bourse. Galectinomics: the road towards the development of new ovarian cancer biomarkers. Canadian cancer research conference (montreal, Canada). Travel award. 1 000 $. (2015).
• Bourse. Galectin-7 increases the invasive behavior of ovarian cancer cells and promotes tumor immune escape. Fondation Armand-Frappier (Laval, Canada). Travel award. 500 $. (2014).
• Subvention. Rôle de la Galectine-7 dans le cancer de la prostate. Fonds de Recherche du Québec (Montreal, Canada). 70 000 $. (2013-2016).
  Numéro de subvention : grant.28132. Voir plus
• Subvention. Role of galectin-7 in prostate cancer. Fondation Armand-Frappier (Laval, Canada). 35 000 $. (2011-2013).
• Bourse. apolipoprotein D function in lipid metabolism. Biomed Conference (Montreal, Canada). 500 $. (2011).
• Subvention. Apolipoprotein D function in lipid metabolism. Royal Bank of Canada (Montreal, Canada). 4 000 $. (2010-2011).
• Subvention. Apolipoprotein D function in lipid metabolism. FARE foundation (UQAM) (Montreal, Canada). 10 000 $. (2009-2011).
• Subvention. Apolipoprotein D function in lipid metabolism. Department of biological sciences (UQAM) (Montreal, Canada). 1 000 $. (2009-2010).

Publications

Articles

• Shi, S.-N., Xu, Q., Liao, Z., Gong, W., Cui, Y., Liu, J., Jiao, X., Wu, Y., Luo, M., Zhang, Y., Wang, L., Wen, Y., Pan, W., Zhao, X., Labrie, M., Ding, Z., Mills, G.B., Ma, D., Zhao, G.-N., ... Fang, Y. (2026). ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer. Drug Resistance Updates. DOI
• Drouin, Z., Lévesque, F., Mouzakitis, K., Labrie, M. (2025). Current preclinical models of brain metastasis. Clinical and Experimental Metastasis. DOI
• Zhao, X., Lai, H., Li, G., Qin, Y., Chen, R., Labrie, M., Stommel, J.M., Mills, G.B., Ma, D., Gao, Q., Fang, Y. (2025). Rictor orchestrates β-catenin/FOXO balance by maintaining redox homeostasis during development of ovarian cancer. Oncogene. DOI
• Mills, G.B., Labrie, M. (2024). Enhancing anticancer activity of macrophages through rational drug combinations. Journal of Clinical Investigation. DOI
• Dareng, E.O., Coetzee, S.G., Tyrer, J.P., Peng, P.-C., Rosenow, W., Chen, S., Davis, B.D., Dezem, F.S., Seo, J.-H., Nameki, R., Reyes, A.L., Aben, K.K.H., Anton-Culver, H., Antonenkova, N.N., Aravantinos, G., Bandera, E.V., Beane Freeman, L.E., Beckmann, M.W., Beeghly-Fadiel, A., ... Gayther, S.A. (2024). Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions. American Journal of Human Genetics. DOI
• del Carmen Crespo Oliva, C., Labrie, M., Allard-Chamard, H. (2024). T peripheral helper (Tph) cells, a marker of immune activation in cancer and autoimmune disorders. Clinical Immunology. DOI
• Lei, J.T., Jaehnig, E.J., Smith, H., Holt, M.V., Li, X., Anurag, M., Ellis, M.J., Mills, G.B., Zhang, B., Labrie, M. (2023). The Breast Cancer Proteome and Precision Oncology. Cold Spring Harbor Perspectives in Medicine. DOI
• Ternes, L., Dane, M., Gross, S., Labrie, M., Mills, G., Gray, J., Heiser, L., Chang, Y.H. (2022). A multi-encoder variational autoencoder controls multiple transformational features in single-cell image analysis. Communications Biology. DOI
• Wei, S., Yin, D., Yu, S., Lin, X., Savani, M.R., Du, K., Ku, Y., Wu, D., Li, S., Liu, H., Tian, M., Chen, Y., Bowie, M., Hariharan, S., Waitkus, M., Keir, S.T., Sugarman, E.T., Deek, R.A., Labrie, M., ... Ashley, D.M. (2022). Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. Clinical Cancer Research. DOI
• Cathcart, A.M., Smith, H., Labrie, M., Mills, G.B. (2022). Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. Expert Review of Proteomics. DOI
• Devries, A.A., Dennis, J., Tyrer, J.P., Peng, P.-C., Coetzee, S.G., Reyes, A.L., Plummer, J.T., Davis, B.D., Chen, S.S., Dezem, F.S., Aben, K.K.H., Anton-Culver, H., Antonenkova, N.N., Beckmann, M.W., Beeghly-Fadiel, A., Berchuck, A., Bogdanova, N.V., Bogdanova-Markov, N., Brenton, J.D., ... Jones, M.R. (2022). Copy number variants are ovarian cancer risk alleles at known and novel risk loci. Journal of the National Cancer Institute. DOI
• Liu, X., Ge, Z., Yang, F., Contreras, A., Lee, S., White, J.B., Lu, Y., Labrie, M., Arun, B.K., Moulder, S.L., Mills, G.B., Piwnica-Worms, H., Litton, J.K., Chang, J.T. (2022). Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. Npj Breast Cancer. DOI
• Pejovic, T., Abate, P.-V., Ma, H., Thiessen, J., Corless, C.L., Peterson, A., Allard-Chamard, H., Labrie, M. (2022). Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases. Frontiers in Oncology. DOI
• Labrie, M., Brugge, J.S., Mills, G.B., Zervantonakis, I.K. (2022). Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nature Reviews Cancer. DOI
• Yu, S., Wei, S., Savani, M., Lin, X., Du, K., Mender, I., Siteni, S., Vasilopoulos, T., Reitman, Z.J., Ku, Y., Wu, D., Liu, H., Tian, M., Chen, Y., Labrie, M., Charbonneau, C.M., Sugarman, E., Bowie, M., Hariharan, S., ... Ashley, D.M. (2021). A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clinical Cancer Research. DOI
• Li, A., Keck, J.M., Parmar, S., Patterson, J., Labrie, M., Creason, A.L., Johnson, B.E., Downey, M., Thomas, G., Beadling, C., Heiser, L.M., Kolodzie, A., Guimaraes, A.R., Corless, C.L., Gray, J.W., Mills, G.B., Bergan, R.C., Mitri, Z.I. (2021). Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. Npj Precision Oncology. DOI
• Parmar, S., Keck, J.M., Kong, B., Look, R., Johnson, B., Patterson, J., Labrie, M., Guimaraes, A.R., Corless, C.L., Beadling, C., Kolodzie, A., Bergan, R., Gray, J.W., Mills, G.B., Mitri, Z.I. (2021). Exceptional response to trastuzumab in a heavily pretreated patient with erbb3-mutated metastatic breast cancer. JCO Precision Oncology. DOI
• Labrie, M., Li, A., Creason, A., Betts, C., Keck, J., Johnson, B., Sivagnanam, S., Boniface, C., Ma, H., Blucher, A., Chang, Y.H., Chin, K., Vuky, J., Guimaraes, A.R., Downey, M., Lim, J.Y., Gao, L., Siex, K., Parmar, S., ... Mitri, Z.I. (2021). Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. Npj Precision Oncology. DOI
• Westin, S.N., Labrie, M., Litton, J.K., Blucher, A., Fang, Y., Vellano, C.P., Marszalek, J.R., Feng, N., Ma, X., Creason, A., Fellman, B., Yuan, Y., Lee, S., Kim, T.-B., Liu, J., Chelariu-Raicu, A., Chen, T.H., Kabil, N., Soliman, P.T., ... Mills, G.B. (2021). Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical Cancer Research. DOI
• Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., Randell, S., Beroard, A., Sugarman, E., Rebecca, V.W., Wei, Z., Lu, Y., Mills, G.B., Field, J., Villanueva, J., ... Guo, W. (2021). Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. DOI
• Sun, C., Fang, Y., Labrie, M., Li, X., Mills, G.B. (2020). Systems approach to rational combination therapy: PARP inhibitors. Biochemical Society Transactions. DOI
• Labrie, M., Kim, T.-B., Ju, Z., Lee, S., Zhao, W., Fang, Y., Lu, Y., Chen, K., Ramirez, P., Frumovitz, M., Meyer, L., Fleming, N.D., Sood, A.K., Coleman, R.L., Mills, G.B., Westin, S.N. (2019). Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. DOI
• Lai, H., Zhao, X., Qin, Y., Ding, Y., Chen, R., Li, G., Labrie, M., Ding, Z., Zhou, J., Hu, J., Ma, D., Fang, Y., Gao, Q. (2019). Correction to: FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer (Journal of Experimental and Clinical Cancer Research (2018) 37 (32) DOI: 10.1186/s13046-018-0696-4). Journal of Experimental and Clinical Cancer Research. DOI
• Shen, J., Zhao, W., Ju, Z., Wang, L., Peng, Y., Labrie, M., Yap, T.A., Mills, G.B., Peng, G. (2019). PARPI triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCANEss. Cancer Research. DOI
• Labrie, M., Kendsersky, N.D., Ma, H., Campbell, L., Eng, J., Chin, K., Mills, G.B. (2019). Proteomics advances for precision therapy in ovarian cancer. Expert Review of Proteomics. DOI
• Fang, Y., McGrail, D.J., Sun, C., Labrie, M., Chen, X., Zhang, D., Ju, Z., Vellano, C.P., Lu, Y., Li, Y., Jeong, K.J., Ding, Z., Liang, J., Wang, S.W., Dai, H., Lee, S., Sahni, N., Mercado-Uribe, I., Kim, T.-B., ... Mills, G.B. (2019). Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell. DOI
• Peng, X., Xu, X., Wang, Y., Hawke, D.H., Yu, S., Han, L., Zhou, Z., Mojumdar, K., Jeong, K.J., Labrie, M., Tsang, Y.H., Zhang, M., Lu, Y., Hwu, P., Scott, K.L., Liang, H., Mills, G.B. (2018). A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. Cancer Cell. DOI
• Lai, H., Zhao, X., Qin, Y., Ding, Y., Chen, R., Li, G., Labrie, M., Ding, Z., Zhou, J., Hu, J., Ma, D., Fang, Y., Gao, Q. (2018). FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein e stimulates the malignant progression of ovarian cancer. Journal of Experimental and Clinical Cancer Research. DOI
• Labrie, M., De Araujo, L.O.F., Communal, L., Mes-Masson, A.-M., St-Pierre, Y. (2017). Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. Scientific Reports. DOI
• Grosset, A.-A., Labrie, M., Vladoiu, M.C., Yousef, E.M., Gaboury, L., St-Pierre, Y. (2016). Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets. Oncotarget. DOI
• Labrie, M., Vladoiu, M., Leclerc, B.G., Grosset, A.-A., Gaboury, L., Stagg, J., St-Pierre, Y. (2015). A mutation in the carbohydrate recognition domain drives a phenotypic switch in the role of galectin-7 in prostate cancer. PLoS ONE. DOI
• Labrie, M., Lalonde, S., Najyb, O., Thiery, M., Daneault, C., Des Rosiers, C., Rassart, E., Mounier, C. (2015). Apolipoprotein D transgenic mice develop hepatic steatosis through activation of PPAR? and fatty acid uptake. PLoS ONE. DOI
• Vladoiu, M.C., Labrie, M., Létourneau, M., Egesborg, P., Gagné, D., Billard, E., Grosset, A.-A., Doucet, N., Chatenet, D., St-Pierre, Y. (2015). Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin. Oncotarget. DOI
• Grosset, A.-A., Labrie, M., Gagn�, D., Vladoiu, M.-C., Gaboury, L., Doucet, N., St-Pierre, Y. (2014). Cytosolic galectin-7 impairs p53 functions and induces chemoresistance in breast cancer cells. BMC Cancer. DOI
• Labrie, M., Vladoiu, M.C., Grosset, A.-A., Gaboury, L., St-Pierre, Y. (2014). Expression and functions of galectin-7 in ovarian cancer. Oncotarget. DOI
• Vladoiu, M.C., Labrie, M., St-Pierre, Y. (2014). Intracellular galectins in cancer cells: Potential new targets for therapy (review). International Journal of Oncology. DOI
• Campion, C.G., Labrie, M., Grosset, A.-A., St-Pierre, Y. (2014). The CCAAT/enhancer-binding protein beta-2 isoform (CEBPβ-2) upregulates galectin-7 expression in human breast cancer cells. PLoS ONE. DOI
• Levros Jr., L.-C., Labrie, M., Charfi, C., Rassart, E. (2013). Binding and repressive activities of apolipoprotein E3 and E4 isoforms on the human ApoD promoter. Molecular Neurobiology. DOI
• Labrie, M., St-Pierre, Y. (2013). Epigenetic regulation of mmp-9 gene expression. Cellular and Molecular Life Sciences. DOI
• Campion, C.G., Labrie, M., Lavoie, G., St-Pierre, Y. (2013). Expression of Galectin-7 Is Induced in Breast Cancer Cells by Mutant p53. PLoS ONE. DOI

Chapitres de livre

• Labrie, M., Fang, Y., Kendsersky, N.D., Li, J., Liang, H., Westin, S.N., Mitri, Z., Mills, G.B. (2019). Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. Advances in Experimental Medicine and Biology. DOI

Autres contributions

Divers

• Wei, S., Du, K., Lan, H., Yang, Z., Deng, Y., Wei, Z., Frederick, D.T., Lee, J., Labrie, M., Tian, T., Moll, T., Chen, Y., Sullivan, R.J., Mills, G., Boland, G.M., Flaherty, K.T., Liu, L., Herlyn, M., Zhang, G. (2024). A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies. Biorxiv.
• Mitri, Z.I., Creason, A.L., Stommel, J.M., Bottomly, D., Ozmen, T.Y., Rames, M.J., Ozmen, F., Jeong, B., Lukashchuk, N., Ashton, J., Lim, J.Y., Sivagnanam, S., Betra, K., Lee, J., Labrie, M., Coussens, L.M., Corless, C.L., McWeeney, S.K., Mills, G.B. (2024). Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial. Medrxiv.
• Ternes, L., Dane, M., Gross, S., Labrie, M., Mills, G., Gray, J., Heiser, L., Chang, Y.H. (2021). ME-VAE: Multi-Encoder Variational AutoEncoder for Controlling Multiple Transformational Features in Single Cell Image Analysis. Biorxiv.
• Westin, S.N., Labrie, M., Litton, J.K., Blucher, A., Fang, Y., Vellano, C.P., Marszalek, J.R., Feng, N., Ma, X., Creason, A., Fellman, B., Yuan, Y., Lee, S., Kim, T.-B., Liu, J., Chelariu-Raicu, A., Chen, T.H., Kabil, N., Soliman, P.T., ... Mills, G.B. (2021). Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer. Medrxiv.
• Johnson, B.E., Creason, A.L., Stommel, J.M., Keck, J.M., Parmar, S., Betts, C.B., Blucher, A., Boniface, C., Bucher, E., Burlingame, E., Camp, T., Chin, K., Eng, J., Estabrook, J., Feiler, H.S., Hu, Z., Kolodzie, A., Kong, B.L., Labrie, M., ... Gray, J.W. (2020). An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. Biorxiv.
• Labrie, M., Li, A., Creason, A., Betts, C., Keck, J., Johnson, B., Sivagnanam, S., Boniface, C., Ma, H., Blucher, A., Chang, Y.H., Chin, K., Vuky, J., Guimaraes, A.R., Downey, M., Lim, J.Y., Gao, L., Siex, K., Parmar, S., ... Mitri, Z.I. (2020). Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations. Medrxiv.
• Shen, J., Zhao, W., Ju, Z., Wang, L., Peng, Y., Labrie, M., Yap, T., Mills, G.B., Peng, G. (2018). PARPi triggers STING-dependent immune response and enhances therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Biorxiv.